Becker's Healthcare November 19, 2024
Private equity firms TowerBrook Capital Partners and Clayton, Dubilier & Rice have completed their $8.9 billion acquisition of R1 RCM.
With the completion of the transaction, R1’s common stock has ceased trading and will no longer be listed on Nasdaq, according to a Nov. 19 R1 RCM news release. The deal was first announced Aug. 1.
With the closing of the deal, Joe Flanagan has reassumed the role of CEO, replacing Lee Rivas. Mr. Flanagan served as R1’s CEO from May 2016 through January 2023. Mr. Flanagan has remained on the company’s board of directors since stepping down as CEO and he will continue serving on the board.
Mr. Rivas became CEO after Mr. Flanagan stepped down...
Today's Sponsors
Today's Sponsor